Closing Bell Nifty ends at around 18,100, Sensex rises 847 pts all sectors in the green - Moneycontrol
| ACBM Stock | USD 0 0.00 0.00% |
About 56% of ACRO Biomedical's investor base is looking to short. The analysis of overall sentiment of trading ACRO Biomedical Co pink sheet suggests that many investors are alarmed at this time. ACRO Biomedical's investing sentiment overview a quick insight into current market opportunities from investing in ACRO Biomedical Co. Many technical investors use ACRO Biomedical stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
ACRO Biomedical pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of ACRO daily returns and investor perception about the current price of ACRO Biomedical Co as well as its diversification or hedging effects on your existing portfolios.
ACRO |
Closing Bell Nifty ends at around 18,100, Sensex rises 847 pts all sectors in the green Moneycontrol
Read at news.google.com
 |
ACRO Biomedical Fundamental Analysis
We analyze ACRO Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ACRO Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ACRO Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
ACRO Biomedical is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
ACRO Biomedical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ACRO Biomedical pink sheet to make a market-neutral strategy. Peer analysis of ACRO Biomedical could also be used in its relative valuation, which is a method of valuing ACRO Biomedical by comparing valuation metrics with similar companies.
Peers
ACRO Biomedical Related Equities
| TRVI | Trevi Therapeutics | 44.58 | ||||
| NGENF | NervGen Pharma | 1.12 | ||||
| ACXP | Acurx Pharmaceuticals | 0.80 | ||||
| ADAG | Adagene | 0.47 | ||||
| XLO | Xilio Development | 0.96 | ||||
| AVTE | Aerovate Therapeutics | 1.54 | ||||
| NUVB | Nuvation Bio | 1.87 | ||||
| IKNA | Ikena Oncology | 2.35 | ||||
| NXTC | NextCure | 3.54 | ||||
| ACLX | Arcellx | 4.09 | ||||
| STOK | Stoke Therapeutics | 5.08 | ||||
| ACRV | Acrivon Therapeutics, | 5.65 | ||||
| MLYS | Mineralys Therapeutics, | 6.02 | ||||
| PTIX | Protagenic Therapeutics | 6.36 | ||||
| HOWL | Werewolf Therapeutics | 7.57 | ||||
| GLUE | Monte Rosa | 8.46 | ||||
| DSGN | Design Therapeutics | 11.01 | ||||
| ANEB | Anebulo Pharmaceuticals | 11.46 |
Other Information on Investing in ACRO Pink Sheet
ACRO Biomedical financial ratios help investors to determine whether ACRO Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ACRO with respect to the benefits of owning ACRO Biomedical security.